论文部分内容阅读
目的:研究心脉隆注射液对冠心病心力衰竭患者血清B型利钠肽(BNP)、超敏C反应蛋白(hs CRP)及血管内皮生长因子(VEGF)的影响情况。方法:冠心病心力衰竭患者90例,按数字表法随机分为对照组42例与观察组48例。两组患者均先实施常规西药治疗方案,在此基础上,观察组加以使用心脉隆注射液进行治疗。对比分析两组患者治疗前后血清BNP、hs CRP、血尿酸(UA)、VEGF、左心射血分数(LVEF)、E/A比值及6MWT情况。结果:经过治疗后,观察组血清BNP(128.44±30.38)pg/L、hs CRP(3.17±0.46)mg/L、UA(430.88±40.62)μmmol/L、VEGF(118.43±19.46)ng/L、LVEF(54.17±10.39)%、E/A比值(0.78±0.08)、6MWT(430.13±60.77)m等均明显优于对照组血清BNP(292.05±70.53)pg/L、hs CRP(3.43±0.55)mg/L、UA(488.35±63.96)μmmol/L、VEGF(98.13±18.56)ng/L、LVEF(47.33±10.25)%、E/A比值(0.63±0.07)、6MWT(397.05±86.79)m,差异有统计学意义(P<0.05)。结论:心脉隆注射液可有效抑制冠心病心力衰竭患者的炎症反应,改善其各项心功能指标,作用效果较优。
Objective: To study the effect of Xinmailong Injection on serum BNP, hs CRP and VEGF in patients with heart failure of coronary heart disease. Methods: 90 patients with coronary heart disease and heart failure were randomly divided into control group (n = 42) and observation group (n = 48) according to the digital table method. Two groups of patients are the first implementation of conventional Western medicine treatment programs, on this basis, the observation group to be treated with heart pulse Long injection. The levels of serum BNP, hs CRP, UA, VEGF, left ventricular ejection fraction (LVEF), E / A ratio and 6MWT were compared between the two groups before and after treatment. Results After treatment, the levels of serum BNP (128.44 ± 30.38) pg / L, hs CRP (3.17 ± 0.46) mg / L and UA (430.88 ± 40.62) μmmol / L and 118.43 ± 19.46 ng / LVEF (54.17 ± 10.39)%, E / A ratio (0.78 ± 0.08) and 6MWT (430.13 ± 60.77) m were all significantly better than those in the control group (292.05 ± 70.53pg / L, hsCRP3.43 ± 0.55) (488.35 ± 63.96) μmmol / L, VEGF (98.13 ± 18.56) ng / L, LVEF (47.33 ± 10.25)%, E / A ratio (0.63 ± 0.07), 6MWT (397.05 ± 86.79) The difference was statistically significant (P <0.05). Conclusion: Xinmailong Injection can effectively inhibit the inflammatory reaction in patients with heart failure of coronary heart disease, and improve their cardiac function indexes, the effect is better.